Cambridge Investment Research Advisors, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $36.4 Billion
- Q3 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 1,271 shares of MDGL stock, worth $672,625. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,271
Previous 1,238
2.67%
Holding current value
$672,625
Previous $375,000
55.47%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding MDGL
# of Institutions
405Shares Held
23.1MCall Options Held
665KPut Options Held
514K-
Baker Bros. Advisors LP New York, NY2.14MShares$1.13 Billion8.0% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $9.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...